Study to Compare the Efficacy and Safety of Two CC-5013 Dose Regimens in Subjects With Metastatic Malignant Melanoma
Status:
Completed
Trial end date:
2004-12-01
Target enrollment:
Participant gender:
Summary
Subjects are randomized to one of two treatment arms. All subjects are screened for
eligibility within 28 days prior to randomization. The study consists of a treatment phase
and a follow-up phase. Subjects will be treated in repeating 4 week cycles.